Zhuo et al. demonstrated that PCIF1 promoted the proliferation and invasion of gastric cancer by targeting TM9SF1.[12] In colorectal cancer, Wang et al. indicated PCIF1 is indispensable for tumorigenesis and can be targeted to enhance the efficacy of immunotherapy.[13] A recent study reported that PCIF1 binds to its cofactor CTBT2, contributing jointly to the development of head and neck squamous cell carcinoma.[50] Despite these advancements, the role of m6Am in RCC remains poorly understood, even though RCC progression was recognized to be closely linked to epigenetic dysregulation. Here, TM9SF1 is linked to head and neck squamous cell carcinoma.